The first patient of the clinical trial of oncolytic bacteria SalMet-Vec® has completed the first intravenous administration at MD Anderson Cancer Center in the United States.
On February 13, 2023, Guangzhou, China, Guangzhou Sinogen Pharmaceutical ("Sinogen") announced that the first patient has successfully completed the first intravenous administration in the phase I/IIa clinical trial for the treatment of advanced solid tumors of Sinogen’s independently developed first-in-class oncolytic bacteria drug, SalMet-Vec®, at MD Anderson Cancer Center in the United States.
At present, two registered clinical trials of intravenous administration and intratumoral administration for the treatment of advanced solid tumors are being carried out simultaneously in the United States and Taiwan, China. The main objective of the clinical trial is to evaluate the safety, tolerance and preliminary efficacy of oncolytic bacteria SalMet-Vec® in the treatment of patients with advanced solid tumors. In addition to MD Anderson Cancer Center, several clinical trial sites in the United States and Taiwan have successively started the recruitment of patients. At the same time, several well-known hospitals under the framework of the "4+4" agreement for cross-strait drug clinical trial review cooperation will also become the global multi-center clinical trial sites for SalMet-Vec®. On the basis of obtaining Phase I clinical safety data, Sinogen will carry out key clinical trials of SalMet-Vec® for liver cancer, osteosarcoma, head and neck cancer, lung cancer, melanoma and other indications. Among them, SalMet-Vec® was granted the Orphan Drug Designation (ODD) by FDA for the treatments of liver cancer and osteosarcoma.
About Oncolytic Bacteria Product SalMet-Vec®
Oncolytic Bacteria Product SalMet-Vec® is a first-in-class genetic engineering biological product that can accurately target and rapidly dissolve tumors . SalMet-Vec® carries specific methionine hydrolase through attenuated Salmonella carrier, depriving the necessary amino acids required for tumor growth, thus killing tumor and preventing tumor proliferation. It is an efficient and tumor-targeting product for broad-spectrum solid tumors. Sinogen Pharmaceutical owns the complete global intellectual property rights of SalMet-Vec®, and it has more than 50 invention patents worldwide and has been authorized for 20.
About Sinogen Pharmaceutical
Sinogen Pharmaceutical is a biopharmaceutical company committed to the development of innovative biological anti-tumor drugs to meet the needs of the global malignant tumor treatment market. The company's vision is to become a Chinese enterprise that continues to develop global innovative drugs.
